Alzheimer's Disease and other Dementias

Mount Sinai's Center for Alzheimer's disease (AD) at The Friedman Brain Institute provides for the integration of clinical care with advanced research efforts aimed at better understanding and treating this and several other forms of dementia, such as Frontotemporal Dementia. Among these efforts are the following:  

Treatment at Mount Sinai

The Center for Cognitive Health (CCH) offers comprehensive evaluation and customized management for the full spectrum of cognitive impairments. Patients coming to us typically have concerns regarding one or more of the following cognitive functions: memory, attention language (e.g., aphasia, dyslexia), visual processing, decision-making, and cognition-related emotional regulation. We offer comprehensive diagnosis for a range of cognitive disorders, including neurologic and psychiatric evaluation, neuropsychological testing, brain scans (MRI, PET, AmyvidTM scans), brain electrical function testing (electroencephalography or EEG), tests of blood and cerebrospinal fluid, and genetic testing. The initial appointment is generally one hour. A customized assessment plan is then arranged for a follow-up visit. These multi-disciplinary examinations comprise the most comprehensive medical evaluation possible, providing the information we need to design a treatment plan best suited for each patient.

These multi-disciplinary examinations comprise the most comprehensive medical evaluation possible, providing the information we need to design a treatment plan best suited for each patient.

Based on the extensive information compiled during our comprehensive diagnostic assessment, we design a coordinated treatment and management plan that integrates a complete range of treatment and services.
These can include: medications, cognitive rehabilitation, physical therapy, counseling, and customized patient care management.

The Center for Cognitive Health collaborates with the National Football League on a joint clinical diagnosis and care delivery practice (CCH-NFLNC).  CCH-NFLNC is one of five such centers affiliated with the NFL.  Former or current NFL players are referred to CCH-NFLNC via staff at the NFL Central Office in Manhattan.  Under the auspices of the Department of Neurology, CCH-NFLNC operates a fellowship program that is open to neurologists, psychiatrists, or rehabilitation medicine physicians.  CCH-NFLNC leadership plays a key role in the development of the new subspecialty in Brain Injury Medicine that will be established by the American Board of Physical Medicine and Rehabilitation in 2014.

Our Research

Mount Sinai has long been a leader in basic and clinical research of Alzheimer's Disease and other dementias. The Mount Sinai Alzheimer's Disease Research Center (ADRC) was one of the first ADRCs established and is now in its 39th year of continuous funding.  The ADRC is structured into service cores (administration, education and outreach, clinical operations, neuropathology) as well as three research projects.  The ADRC projects in the current round of the Center focus on the role of biomarkers, inflammation, and vascular factors in the cause and treatment of dementia.

Clinical Trials

Scientists can learn a tremendous amount about dementia and the brain from studying healthy people as well as those with memory disorders. Therefore, the ADRC conducts several types of clinical research for healthy elders and those with memory disorders. ADRC Clinical Trials evaluate the safety and effectiveness of new medications in treating or preventing AD. Other studies examine genetic factors and biological markers in AD, as well as factors that might either increase or decrease the risk of getting AD.